← All trials
NCT07250646
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2026
- Primary completion
- Oct 31, 2027
- Completion date
- Apr 30, 2028
- First posted
- Nov 26, 2025
- Last posted
- Nov 26, 2025
- Enrollment
- 28
- Arms / groups
- — / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aspera Biomedicines, Inc.Lead sponsor
- TEMPUSCollaborator
- University of California, San DiegoOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.